Explore a continuación la lista completa de nuestras notas de prensa (página 21 de 28):
Stanford Medicine research on GLP-1 receptor variability raises critical questions for formulation strategy, dosing study design, and next-generation GLP-1 pipelines.
Tobinco Pharmaceuticals is urging Ghana's government to support local drug manufacturing, highlighting quality misconceptions and import competition as key barriers.
Alembic Pharmaceuticals incorporates Alembic Pharmaceuticals GmbH in Germany to manage EU sales, distribution, and regulatory operations directly.
Roche and Zealand Pharma's amylin weight-loss candidate signals growing CDMO demand. Plant heads must assess sterile manufacturing and process validation capacity now.
US envoy Sergio Gor signals deeper US-India pharma cooperation. What it means for API supply chains, GMP alignment, and FDA-CDSCO regulatory harmonization.
Alembic Pharmaceuticals secures USFDA approval for Fingolimod 0.5 mg Capsules, entering a $145M U.S. multiple sclerosis generics market previously held by Novartis.
Medvi's $1.8B telehealth model and FDA warning reveal compounding loopholes impacting 503B facilities and GLP-1 post-shortage enforcement rules.
Rajasthan orders recall of 7 NSQ drug batches including Cefixime, Albendazole, and Ciprofloxacin under the Drugs and Cosmetics Act, 1940.
Alembic Pharmaceuticals secures USFDA approval for generic Fingolimod capsules, entering a $145M U.S. multiple sclerosis market previously led by Novartis.
A Gurugram operator manufactured counterfeit Mounjaro and an unsterile tirzepatide injectable, revealing supply chain and packaging authentication failures across India.
Novartis clears WHO prequalification for a pediatric three-drug fixed-dose combination antimalarial, setting new GMP and formulation benchmarks for CMOs in global health supply chains.
Rising generic medicine demand driven by cost-of-living concerns is pressuring manufacturers on GMP compliance, capacity planning, and supply chain agility.
A U.S. executive order prioritising psychedelic breakthrough therapies is exposing critical GMP gaps for manufacturers. What QA and regulatory leads must do now.
Sam Pharmaceuticals launches a WHO-standard manufacturing facility in Nigeria backed by FCMB and BoI, targeting import reduction and GMP compliance in West Africa.
Indian Immunologicals hits Rs 1,586 crore in FY26 revenue with a 16% decade-long CAGR. What it means for global vaccine supply chains and biologics manufacturing.
Sun Pharma's $11.75B all-cash acquisition of Organon triggers GMP integration challenges, regulatory site transfers, and biosimilar portfolio realignment.
Sun Pharma's $11.75B acquisition of Organon expands biosimilars and women's health scale. Key GMP, ICH Q10, and regulatory harmonization implications for plant and QA teams.
Alembic Pharmaceuticals secures FDA final approval for Fingolimod 0.5 mg capsules, a generic to Novartis Gilenya. Key ANDA and GMP implications for MS generics manufacturers.
Novartis secures EC approval for Rhapsido (remibrutinib) as the first oral targeted CSU therapy in Europe. Key implications for QA, regulatory, and manufacturing teams.
Zydus secures DCGI approval for Phase III trials of oral anti-malarial Zintrodiazine. What RA teams and QA directors need to know about multi-centre compliance.
Eton Pharmaceuticals doses first patient in ET-700 pilot trial testing extended-release zinc acetate for Wilson disease. Topline data expected H2 2026.
Medicus Pharma met with House Energy and Commerce leaders to advance Orphan Drug Designation and registrational IND approval for SkinJect in Gorlin Syndrome.
Cipla wins USFDA approval for the first AB-rated generic of Ventolin HFA, advancing Indian pharma competitiveness in complex inhaler generics.
Former Cipla MD Umang Vohra appointed Executive Chairman and Group CEO of Cohance Lifesciences as Vivek Sharma moves to advisory role.
Sionna Therapeutics completes PreciSION CF Phase 2a enrollment for SION-719, the first NBD1 stabilizer in clinical CF trials. Topline data expected summer 2026.
Krystal Biotech's VYJUVEK receives its third FDA approval action since 2023. What the September 2025 letter means for gene therapy post-approval lifecycle management.
FDA eliminated YESCARTA's REMS in June 2025. QA directors and regulatory leads must now reassess CAR-T risk management frameworks and GMP compliance obligations.
Cabaletta Bio presents GMP comparability and automated CAR-T manufacturing data via Cellares Cell Shuttle at ASGCT 2026, with implications for ATMP process validation.
Biomea Fusion's COVALENT-112 Phase 2 data show durable C-peptide preservation 40 weeks post-dose in T1D. Key implications for pipeline and CMC planning.
NurExone secures Australian patent on stem cell-derived exosome production, expanding its international IP portfolio as manufacturing scale-up plans advance with BioXtek.
CDER proposes TAVNEOS withdrawal after manipulated pivotal trial data and undisclosed analyses. Key implications for QA directors and regulatory affairs teams.
FDA's ODAC meets April 30 to review AstraZeneca's camizestrant and capivasertib NDAs. Key implications for biomarker-driven oncology approvals and manufacturing readiness.
Eight FDA oncology approvals in Q1 2026 including relacorilant, nivolumab-AVD, and teclistamab combinations require immediate GMP and labeling action from QA and regulatory teams.
Lilly acquires Ajax Therapeutics for up to $2.3B, gaining a first-in-class Type II JAK2 inhibitor in Phase 1 for rare blood cancers. Key implications for GMP and regulatory teams.
Samsung Bioepis Q2 2026 report logs 92 US biosimilar approvals. QA directors and regulatory leads face rising interchangeability and comparability standards.
Piramal Pharma Solutions appoints Gregory Judge as Director to lead large-molecule biologics partnerships in Europe, signaling CDMO expansion intent.
Boehringer Ingelheim's survodutide achieves 16.6% weight loss in Phase III SYNCHRONIZE-1 trial, raising fill-finish and CMO capacity questions for the GLP-1 sector.
Novartis Q1 2026 regulatory milestones -- Cosentyx pediatric HS approval, Fabhalta and ianalumab priority reviews, Avidity acquisition -- stress-test CMC and supply chain capacity.
Jamjoom Pharma signs agreement to acquire Pfizer's OSD manufacturing facility in KAEC, Saudi Arabia. Key implications for GMP transitions and MEA supply chains.
Novo Nordisk presents 52 abstracts at ECO 2026 covering oral, higher-dose, and combination semaglutide. Key implications for CDMOs, API suppliers, and process validation.
Sam Pharmaceuticals commissions a WHO-GMP facility in Ota, Nigeria, with 400M+ tablet monthly capacity and NGN 6.2B in development financing.
Sun Pharma acquires Organon at 5-6x EBITDA, entering the global biosimilar top 10. What QA directors and plant heads must prepare for post-merger.
Former Cipla CEO Umang Vohra takes the helm at Cohance Lifesciences as Executive Chairman and Group CEO, reshaping the CDMO's API and complex molecule strategy.
AbbVie submits sNDA for upadacitinib (RINVOQ) in severe alopecia areata. Phase 3 UP-AA data, FDA review implications, and manufacturing considerations for QA and plant heads.
Cosette Pharmaceuticals names Erika Tooman SVP and General Counsel to manage legal, compliance, and governance as the specialty pharma firm scales through acquisitions.
FDA approved ZEGFROVY (sunvozertinib) for EGFR exon 20 NSCLC on July 2, 2025. Dizal (Jiangsu) enters U.S. oncology market, raising GMP and foreign facility compliance questions.
Regeneron's LYNOZYFIC FDA approval for relapsed myeloma highlights fill-finish precision and cold-chain integrity challenges tied to step-up dosing protocols.
KalVista's EKTERLY (sebetralstat) gains FDA approval as the first oral on-demand HAE tablet. What it means for solid-dose manufacturing and regulatory strategy.
Leo Pharma's ANZUPGO (delgocitinib) approved July 2025 for chronic hand eczema. What the first topical JAK inhibitor means for GMP manufacturing and QA teams.
FDA approved PTC Therapeutics' SEPHIENCE for PKU on July 28, 2025. Weight-based oral powder dosing from one month raises GMP and process validation considerations.
Insmed's BRINSUPRI approved August 2025 as first DPP1 inhibitor for non-cystic fibrosis bronchiectasis. What manufacturing and regulatory teams need to know.
Eli Lilly partners with an AI startup on next-generation gene editors. What QA directors and process validation leads need to know about GMP and ICH Q10 impact.
CSL Behring's ANDEMBRY approved for monthly HAE prevention. What the Phase 3 trial design and subcutaneous format mean for biologics manufacturing and cold-chain logistics.
Eledon Pharmaceuticals' tegoprubart advances in a crowded T1D biologic pipeline. What it means for CMO capacity, process validation, and BLA readiness.
Genzyme's WAYRILZ (rilzabrutinib) approved for ITP. Key GMP, containment, and process validation considerations for manufacturing teams and regulatory affairs leads.
Ionis Pharmaceuticals' DAWNZERA approval sets GMP and regulatory benchmarks for subcutaneous ASO injectables. Key implications for CDMOs and biologics facilities.
FDA approved Kura Oncology's KOMZIFTI for NPM1-mutant relapsed/refractory AML via single-arm trial. Key implications for regulatory, CMC, and QA teams.
Arrowhead's REDEMPLO (plozasiran) approval for FCS sets a regulatory and CMC benchmark for oligonucleotide injectable manufacturers and CDMOs.
FDA approved LIB Therapeutics' LEROCHOL in December 2025. Learn what the once-monthly subcutaneous PCSK9 inhibitor means for fill-finish and CDMO operations.
FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC, but a China-only pivotal trial and 76% Asian safety dataset raise ICH E5 and inspection compliance questions.
FDA's accelerated approval of Jazz Pharmaceuticals' MODEYSO for H3 K27M-mutant glioma sets a multi-trial submission precedent for rare pediatric oncology.
B. Braun recalls two lots of Lactated Ringer's Injection 1L over cellulose and stearate particulates. QA teams should review complaint investigation SOPs now.
Eli Lilly's $2.3B acquisition of Ajax Therapeutics expands its blood cancer pipeline, with major implications for GMP planning and CMC regulatory submissions.
Arcera Life Sciences and Fosun Pharma establish a cross-border licensing framework for oncology and neuroscience assets, raising GMP and regulatory alignment questions.
MetaShape Pharma AG presents MS-001 plus semaglutide preclinical data at ADA 2026. What formulation and GMP challenges should CDMOs anticipate for GLP-1 combinations?
Henrik Krüpper becomes CEO of Unither Pharmaceuticals as the CDMO advances a 2026 facility build-out. What it means for contract clients and GMP operations.
GlaxoSmithKline's EXDENSUR (depemokimab) approved for severe eosinophilic asthma with twice-yearly dosing. Key manufacturing and QA implications for pharma teams.
Cytokinetics' MYQORZO (aficamten) approved December 2025 for oHCM. Pharma Now examines CMC, GMP, and QA implications for cardiac myosin inhibitor manufacturers.
Leinco Technologies and CellCarta partner to advance proteomics from pilot-scale research to high-volume clinical manufacturing in immuno-oncology. Key implications for CDMOs and QA teams.
FDA's ODAC meets April 29 to review AstraZeneca's camizestrant NDA for HR+HER2- breast cancer after a nine-month advisory committee hiatus.
FDA approves AstraZeneca's Breztri while a Kansai OTC acquisition raises GMP compliance and supply chain questions for global pharma operations.
Merck partners Remepy on PDURS-focused drug-software integration. What QA directors and regulatory affairs leads need to know about compliance implications.
Sanofi Consumer Healthcare's Q1 FY26 results show 33% revenue growth and 15.5% domestic sales rise driven by recalled product relaunch. A case study for QA professionals.
PHARMAP 2026 in Amsterdam explores Pharma 4.0, outsourcing, digital transformation, resilient supply chains, and patient‑centric packaging across global pharma manufacturing.
Pfizer's Delaware patent settlements extend VYNDAMAX exclusivity to June 2031, delaying generic tafamidis entry and reshaping cardiovascular pipeline strategies.
Exciva doses first patient in Phase 2/3 SERENADA trial for Alzheimer's agitation drug Deraphan, backed by EUR 53M Series B. QA and manufacturing implications examined.
Kyverna's miv-cel posts 46% walk improvement in SPS phase 2. What autologous CAR-T manufacturers and GMP facilities must prepare for as a BLA pathway nears.
OneSource Pharma and Dr. Reddy's secure Health Canada approval for generic Semaglutide Injection, with supply from an FDA-approved Bengaluru CDMO facility.
FDA approves AstraZeneca's Breztri for asthma. Pharma Now examines GMP, device-drug interface, and process validation implications for inhaler manufacturers.
Novartis and PTC advance Huntington's drug to Phase 3 with a 2030 timeline, but silence on accelerated approval leaves CMC and regulatory teams in planning limbo.
AstraZeneca and GSK report strong oncology revenues. What sustained blockbuster demand means for biologics capacity planning and GMP supply chain resilience.
Tonix Pharmaceuticals targets H1 2027 for an adaptive Phase 2 field study of TNX-4800, an anti-OspA monoclonal antibody for Lyme disease prevention, pending FDA agreement.
Teva's FDA approval of denosumab biosimilar PONLIMSI and omalizumab filing accepted by FDA and EMA signal mounting biologics manufacturing demands ahead of 2027 revenue targets.
Regeneron's Otarmeni FDA approval as the first gene therapy for genetic hearing loss raises urgent GMP, viral vector scale-up, and ATMP manufacturing questions.
Teva's $700M acquisition of Emalex Biosciences targets a 2H 2026 NDA for ecopipam, a first-in-class D1 antagonist for pediatric Tourette syndrome with Orphan Drug designation.
Purdue Pharma ordered to pay $5.5B in opioid ruling. What the verdict means for pharma QA, pharmacovigilance, and corporate governance under ICH Q10.
LogiPharma benchmarking reveals pharma supply chains are operational but lack real-time visibility and collaboration. Key priorities for plant heads in 2026.
EMA's new quarterly vaccine confidence advisory group signals tighter benefit-risk communication expectations. What regulatory affairs and QA teams need to know.
AbbVie's Q1 2026 results show Skyrizi at $4.48B and Rinvoq at $2.12B, reshaping GMP manufacturing priorities as Humira revenues fall 40% operationally.
WHO validates Australia as the 30th country to eliminate trachoma as a public health problem, following two decades of community-integrated NTD intervention.
Boehringer Ingelheim and Eko Health launch CANINEBEAT AI, detecting canine heart murmurs with 95%+ sensitivity. US and UK rollout underway.
A major preclinical review links GLP-1 drugs to reduced Alzheimer's protein buildup. What this means for GMP manufacturers planning capacity and regulatory strategy.
Sun Pharma's acquisition of Organon, a Merck spin-off covering 25 pharma companies, targets top-three global generics standing. Key implications for GMP integration and supply dynamics.
AstraZeneca commits £300m to UK operations, announced by PM Starmer. Key implications for GMP infrastructure, process validation, and regulatory strategy.
Chiesi's ELFABRIO approval on 93 patients sets a regulatory benchmark for rare disease biologic manufacturers. Key insights for QA and regulatory affairs leads.
Piramal Pharma targets ADC manufacturing and semaglutide API production as chair Nandini Piramal cites complex drug demand as a key earnings driver for the CDMO.
Sanofi appoints Belén Garijo as CEO from May 1, 2026. Her mandate on execution discipline signals shifts in manufacturing investment and QA priorities.
Eli Lilly's EBGLYSS FDA approval across 16 countries offers regulatory affairs teams a reference model for multi-country biologics clinical data packages.
FDA approved MIPLYFFA for Niemann-Pick disease Type C on a 39-patient trial. What this means for orphan drug regulatory submissions and manufacturing standards.
FDA approved COBENFY for schizophrenia in Sept 2024. Bristol Myers Squibb's fixed-dose muscarinic combination capsule raises GMP, validation, and 21 CFR Part 211 compliance questions.
IntraBio's AQNEURSA approval for Niemann-Pick disease Type C highlights oral suspension formulation complexity for CDMOs and specialty pharma manufacturers.
GE Healthcare's FLYRCADO FDA approval spotlights GMP requirements for F-18 radiopharmaceuticals. Key insights for nuclear pharmacy QA and manufacturing leads.
Genentech's FDA-approved inavolisib triple regimen raises GMP coordination and process validation challenges for plant heads and QA directors in oncology manufacturing.
Pfizer's HYMPAVZI FDA approval for hemophilia A and B prophylaxis raises fill-finish, device, and supply chain requirements for biologics manufacturers.
Astellas' VYLOY FDA approval for CLDN18.2-positive gastric cancer raises companion diagnostic integration and IV production scalability questions for QA teams.
FDA approved Iterum Therapeutics' ORLYNVAH oral penem tablet for uUTI in October 2024. QA and manufacturing teams face new GMP, API, and process validation demands.
Syndax's REVUFORJ FDA approval for KMT2A leukemia in patients aged 1+ raises process validation and GMP demands for oral solid dose oncology manufacturers.
FDA granted accelerated approval to Jazz Pharmaceuticals' ZIIHERA for HER2-positive biliary tract cancer. Key implications for QA, GMP, and bispecific antibody manufacturing.
FDA approved BridgeBio Pharma's ATTRUBY (acoramidis) for ATTR-CM in November 2024. Key Phase 3 trial data, dosing distinctions, and manufacturing considerations for CMOs and regulatory teams.
FDA approved RAPIBLYK based solely on trials in China and Japan. Regulatory affairs teams must assess what this means for foreign clinical data submissions.
Bracco Diagnostics' IOMERVU (iomeprol) approval across multiple imaging indications raises sterile injectable compliance and regulatory submission complexity for QA teams.
Zealand Pharma and Roche advance petrelintide to Phase 3 in H2 2026. CDMOs face co-formulation and GMP scale-up demands for this once-weekly amylin analog.
FDA issues April 28, 2026 approval letter for Grifols GAMUNEX-C (STN BL 125046) with Clinical Pharmacology Review. Key compliance implications for QA and regulatory teams.
Telix's OPTIMAL-PSMA Phase 2 trial shows TLX597-Tx has low organ uptake and higher tumor targeting, supporting dose intensification and a new mHSPC study.
FDA approved Cymabay's LIVDELZI for primary biliary cholangitis in 2024. What QA directors and regulatory leads need to know about the approval pathway.
Incyte's NIKTIMVO approval as an IV CSF1R inhibitor for chronic GVHD raises sterile fill-finish and regulatory strategy questions for rare disease biologic manufacturers.
Janssen's LAZCLUZE plus amivantamab approval for EGFR-mutant NSCLC raises manufacturing, QA, and regulatory complexity for oncology plant heads and compliance teams.
PCI Pharma Services commits $1B to sterile fill-finish and device assembly. What plant heads and QA directors need to know about CDMO capacity reshaping.
Fertin Pharma names Aditya Sharma as Managing Director for India, signalling potential CDMO and consumer wellness manufacturing expansion in the subcontinent.
Zydus Lifesciences acquires France-based FBC Medical through Amplitude SAS to expand EU distribution and reduce logistics costs. Analysis for pharma ops leaders.
AstraZeneca opens a new API manufacturing site in Dublin. Pharma Now examines GMP readiness, regulatory approval timelines, and Ireland's life sciences role.
US FDA issued 7 Form 483 observations to Alkem Laboratories after a 12-day GMP inspection at its Daman Amaliya facility in April-May 2026.
CuraTeQ Biologics receives Health Canada Notice of Compliance for bevacizumab biosimilar Bevqolva. Key implications for biosimilar manufacturers and oncology market access.
OpenAI launches GPT-Rosalind, a domain-specific AI model built for biochemistry and genomics reasoning, accelerating drug discovery and life sciences research workflows.
Gufic Biosciences deepens its stake in Australian immunotherapy firm Selvax, targeting human and veterinary oncology. Implications for CDMO and biologics strategy.
AstraZeneca opens a $360M API facility in Dublin, advancing regional supply resilience amid U.S. tariffs. Key implications for GMP site strategy and regulatory planning.
OneSource Specialty Pharma enables Canada's second generic semaglutide approval, underscoring CDMOs as critical partners in the GLP-1 generics manufacturing race.
Pasithea Therapeutics appoints Kartik Krishnan, M.D., Ph.D. as CMO. His cobimetinib FDA approval experience shapes PAS-004 strategy for NF1 rare disease development.
UCB's $2.2bn acquisition of Candid Therapeutics accelerates T-cell engager development in autoimmune disease, raising GMP and process validation demands for CDMOs and biologics facilities.
France fines Novo Nordisk and Eli Lilly €1.7m over Wegovy and Mounjaro ad campaigns. What EU regulatory affairs teams must review now.
Vertex Pharmaceuticals' international regulatory leadership outlines a CMC and manufacturing readiness framework for early-stage biopharma companies facing submission risk.
Ardena names Ben Ash CFO and Henny Zijlstra CCO as the Belgian CDMO scales its nanomedicine, drug conjugate, and bioanalytical platform internationally.
ten23 health completes fill-finish testing of the West Synchrony S1 PFS system, reducing manufacturing risk for biologics and vaccine CDMO programs.
FDA advisory panel backs AstraZeneca's prostate cancer combination on CAPItello-281 Phase III data. Key implications for regulatory pathway and manufacturing scale-up.
Health Canada clears Aurobindo Pharma's bevacizumab biosimilar under Food and Drug Regulations, challenging Roche's Avastin in the Canadian oncology market.
Sunshine Lake Pharma secures FDA interchangeable biosimilar status for insulin, challenging Sanofi and Eli Lilly in the US market. Key implications for supply chain and QA.
FDA clears vepdegestrant (Veppanu) for breast cancer, making Pfizer and Arvinas the third oral SERD entrant. Key GMP and regulatory implications for manufacturers.
Haleon relaunches Centrum Adults 50+ in Canada with cognitive health claims backed by Harvard-affiliated RCT data. Key read for regulatory and pharmacy teams.
Mirum Pharmaceuticals reports volixibat met its primary endpoint in the VISTAS PSC trial. NDA preparation, process validation, and CMC considerations now in focus.
LIFEPharma plans a Dh700m GMP pharma manufacturing hub in Abu Dhabi. What it means for Gulf supply chains, ICH Q10 compliance, and emerging market capacity.
FibroBiologics releases first cGMP batch of fibroblast therapy CYWC628 for Phase 1/2 diabetic foot ulcer trial, clearing all FDA safety and quality testing requirements.
Abeona Therapeutics' Q1 2026 call on May 13 puts its autologous cGMP manufacturing model for ZEVASKYN under scrutiny. Key watch for QA and regulatory affairs leads.
Eastman Kodak's pharma unit and SUNY Geneseo launch a collaborative hub to train graduates for GMP-regulated biotech and pharmaceutical manufacturing roles.
Foundation Medicine launches FoundationOne PGx with Fulgent Genetics to profile pharmacogenetic effects and PK variability in cancer drug development.
Vanda Pharmaceuticals launches NEREUS, the first motion sickness treatment approved in over 40 years. What it means for FDA regulatory strategy and GMP scale-up.
The Supreme Court restores mifepristone access via telehealth, mail, and pharmacies. What manufacturers and specialty pharmacies must know about REMS obligations.
FDA issues fifth ASCENIV approval letter for ADMA Biologics and extends expiry on six 2019-2020 lots. Key compliance context for biologics QA and regulatory teams.
FDA approves selumetinib granules for NF1 patients from age 1 using bioavailability bridging. Key implications for CMC teams and pediatric formulation development.
Neuland Labs reports Japanese pharma companies are engaging CDMOs at the preclinical stage, with implications for capacity planning and tech transfer timelines.
Pharco Pharmaceuticals commits EGP 1.5bn to build an African generics manufacturing network, raising GMP compliance and IP flexibility questions for the industry.
FDA converts pembrolizumab to traditional approval for HER2-positive gastric cancer. KEYNOTE-811 OS and PFS data, GMP implications, and supply chain impact analyzed.
Lexicon Pharmaceuticals closes a $100M milestone-gated debt facility with Hercules Capital, replacing Oxford Finance and funding late-stage cardiometabolic pipeline programs.
Viatris CFO Doretta Mistras departs May 22, 2026. Paul Campbell steps in as interim CFO ahead of Q1 earnings. What it means for manufacturing investment.
FDA GDUFA Type II API DMF payment data shows 147 receipts through May FY2026. Analyze what shifting submission volumes mean for generics pipelines and API sourcing.
UCB's acquisition of Candid Therapeutics triggers technology transfer, GMP alignment, and regulatory filing reviews. What plant heads and QA directors need to know.
Aurobindo Pharma confirms Dr. Sanjay Chaturvedi's resignation as CEO of API subsidiary Apitoria Pharma. Successor search underway. Supply chain implications assessed.
The Supreme Court temporarily restores mifepristone access via telehealth and mail. Here is what manufacturers and specialty pharmacies must do now under REMS.
Pharco Pharmaceuticals plans a $28M integrated manufacturing network across Africa. QA directors and supply-chain leads face new GMP and vendor qualification challenges.
Kuehne+Nagel's new GDP-compliant Hyderabad facility reshapes cold chain logistics for Indian API exporters and MNC pharma supply chains targeting EU and US markets.
ImmuPharma initiates IND-enabling activities for Kapiglucagon glucagon prodrug, engaging tranScrip for pre-IND FDA meeting and 505(b)(2) regulatory strategy evaluation.
Novartis commits $23B to US manufacturing with a seventh site, a dedicated API facility in Morrisville, NC targeting solid dosage and RNA therapeutics supply chains.
AbbVie's 18 DDW 2026 abstracts show risankizumab's 14% switch rate and upadacitinib's hospitalization data, key signals for biologic CMC and supply planning.
Filana Therapeutics is resolving a December 2025 FDA Clinical Hold on its simufilam IND for TSC epilepsy. A case study in 21 CFR Part 312.42 hold response strategy.
Zentalis doses first patient in ASPENOVA Phase 3 for azenosertib in platinum-resistant ovarian cancer, running parallel to DENALI accelerated approval pathway.
Madrigal licenses Arrowhead's ARO-PNPLA3 siRNA for MASH, with Phase 1 NEJM data showing 46% liver fat reduction. CMC and R&D implications examined.
India's pharma exports topped $31B in FY26 as the US market contracted 11.54%. What this signals for global generic sourcing, supplier qualification, and supply-chain resilience.
Emirates Drug Establishment and Arcera sign an MoU to build UAE pharmaceutical manufacturing capacity. Key implications for GMP compliance and market access.
Dupixent's REMODEL Phase 4 trial shows structural esophageal improvement at week 24 in EoE, with implications for label expansion, sBLA timelines, and biologics manufacturing capacity.
Cellectar Biosciences closes a $140M financing to fund an NDA for accelerated approval of iopofosine I 131 in Waldenström macroglobulinemia. Q4 2026 confirmatory study launch is the key CMC checkpoint.
IDEAYA Biosciences initiates RTOR submission for darovasertib NDA in uveal melanoma. A live case study in accelerated approval sequencing for regulatory affairs teams.
India revises its rare disease policy, raising patient funding to Rs 50 lakh and mandating indigenous therapy development, key implications for pharma R&D and CDSCO strategy.
A renewed government call for an EU pharma-medtech strategic taskforce signals potential GMP harmonisation and supply chain resilience shifts for EU-market manufacturers.
OneSource Specialty Pharma earns Health Canada approval for generic semaglutide, the second GLP-1 injectable clearance in Canada. Key read for QA and regulatory leads.
Barclays raises Eli Lilly's price target to $1,400 on tirzepatide momentum. Supply-chain leads must assess whether Lilly's $9B+ manufacturing build tracks real demand.
Sanofi's $294M Toronto AI hub expansion sets a new benchmark for AI in GMP manufacturing. What QA directors and plant heads must validate before inspection.
Amylyx Pharmaceuticals opens a U.S. Expanded Access Program for post-bariatric hypoglycemia. Learn what GMP, labelling, and IND annual report obligations apply to manufacturing and QA teams.
Envirotainer appoints Aymeric Chandavoine as CEO as pharma cold chain logistics faces tighter regulatory scrutiny and rising biologic distribution demand.
Pfizer's profit dip signals accelerated oncology and obesity pipeline investment. Plant heads and QA directors face compressed process validation and GMP scale-up timelines.
Madrigal licenses Arrowhead's ARO-INHBE for up to $1B, accelerating RNAi MASH pipeline activity. What CDMOs and CMC teams need to assess now.
FDA's CBER formalises CMC flexibility for CGT biologics license applications under docket FDA-2026-D-4692. Key implications for CMC teams, QA directors, and regulatory leads.
CDER's May 2026 OMUFA briefing covers FY2026 fee rates, OTC monograph facility registration, payment timelines, and non-payment penalties under the OMUFA II framework.
FDA's updated CGMP Q&A clarifies media fill frequency, process validation batch requirements, ISO 14644 limits, and PAT implementation under 21 CFR Part 211.
Biomea Fusion's icovamenib earns three ADA late-breaking poster slots in June 2026. Here's what CMC and process development teams need to track before Phase 3.
Eli Lilly terminates ocadusertib collaboration with Rigel effective June 2026. Rigel refocuses on IRAK1/4 inhibitor R289 in MDS with Phase 2 dose selection due H2 2026.
Verrica Pharmaceuticals presents VP-315 Phase 2 data showing 86% tumour reduction and abscopal-like regression in untreated BCC lesions at SID 2026. Key read for regulatory and R&D teams.
FDA's section 505B(d)(1) non-compliance table now lists 195 entries. Regulatory affairs teams should audit PREA postmarketing timelines and deferral extension windows now.
Samsung Bioepis' SB27 met Phase 1 PK bioequivalence endpoints in NSCLC patients. What CMC and regulatory teams need to track as the pembrolizumab biosimilar race intensifies.
FDA issued five procedural Form 483 observations after a pre-license inspection at Biocon Biologics' Bengaluru site. What it means for biosimilar BLA timelines.
Ajanta Pharma's Q4 FY26 revenue rose 21% to Rs 1,422 crore as US generics jumped 49%. What mid-tier Indian manufacturers should benchmark against this result.
Laurus Labs posts 23% FY26 revenue growth and Rs 279 crore Q4 profit. What the CDMO scale-up means for plant heads and supply-chain outsourcing decisions.
Evotec's Horizon transformation enters implementation as Q1 2026 revenues dip. What QA directors and alliance leads need to track in the INDiGO platform build-out.
Novo Nordisk's Wegovy pill tops 2M US prescriptions in Q1 2026. What plant heads and supply-chain directors need to know about peptide and oral solid dose scaling.
Caplin Steriles receives USFDA approval for Calcium Gluconate Injection, targeting a $71M US market. Key compliance insights for QA directors and sterile injectable sites.
Tonix Pharmaceuticals secures GPO coverage for TONMYA cyclobenzaprine sublingual tablets, reaching 35 million U.S. commercial lives. Medicare talks ongoing.
Madrigal licenses Arrowhead's ARO-PNPLA3 GalNAc-siRNA for MASH as Rezdiffra Q1 sales reach $311.3M. Key manufacturing and regulatory implications for CDMOs.
Medicus Pharma's D-MNA hits 55% complete response in Phase 2 SKNJCT-003 BCC trial. Expanded dose-response data supports FDA End-of-Phase 2 discussions.
Cipla launches Ciposcillo, a next-generation oscillometer for early COPD and asthma diagnosis. Key details on device strategy, regulatory pathway, and procurement implications.
FDA converts rucaparib's accelerated approval to regular status for BRCAm mCRPC. Key implications for CDx compliance, GMP, and regulatory teams managing post-approval obligations.
FDA's one-day inspectional assessment pilot launched April 2026 across multiple inspectorates. Learn what NAI outcomes and escalation authority mean for QA and plant operations.
FDA CDER publishes EL-PFDD meeting dates for 13 rare disease areas through Feb 2027. Key signal for regulatory affairs and CMC manufacturing teams.